{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:40:46Z","timestamp":1777387246944,"version":"3.51.4"},"reference-count":168,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/100000049","name":"NIA, National Institute on Aging","doi-asserted-by":"publisher","award":["R15AG050292-01"],"award-info":[{"award-number":["R15AG050292-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"NIA, National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG064479-01"],"award-info":[{"award-number":["R21AG064479-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The metabolic peptide hormone amylin, in concert with other metabolic peptides like insulin\nand leptin, has an important role in metabolic homeostasis and has been intimately linked to\nAlzheimer\u2019s disease (AD). Interestingly, this pancreatic amyloid peptide is known to self-aggregate\nmuch like amyloid-beta and has been reported to be a source of pathogenesis in both Type II diabetes\nmellitus (T2DM) and Alzheimer\u2019s disease. The traditional \u201cgain of toxic function\u201d properties assigned\nto amyloid proteins are, however, contrasted by several reports highlighting neuroprotective\neffects of amylin and a recombinant analog, pramlintide, in the context of these two diseases. This\nsuggests that pharmacological therapies aimed at modulating the amylin receptor may be therapeutically\nbeneficial for AD development, as they already are for T2DMM. However, the nature of amylin\nreceptor signaling is highly complex and not well studied in the context of CNS function. Therefore,\nto begin to address this pharmacological paradox in amylin research, the goal of this review is\nto summarize the current research on amylin signaling and CNS functions and critically address the\nparadoxical nature of this hormone's signaling in the context of AD pathogenesis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x19666211201093147","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T05:15:46Z","timestamp":1638422146000},"page":"1894-1907","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Amylin Pharmacology in Alzheimer\u2019s Disease Pathogenesis and Treatment"],"prefix":"10.2174","volume":"20","author":[{"given":"Gemma","family":"Casadesus","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Florida, Gainesville, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel R.","family":"Corrigan","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Kent State University, Kent, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Piontkivska","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Kent State University, Kent, USA"},{"name":"Department of Biological Sciences, Kent State University,\nKent, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"Alzheimer\u2019s"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1212\/WNL.0000000000000240","volume":"82","author":"James B.D.","year":"2014","unstructured":"James B.D.; Leurgans S.E.; Hebert L.E.; Scherr P.A.; Yaffe K.; Bennett D.A.; Contribution of Alzheimer disease to mortality in the United States. Neurology 2014,82(12),1045-1050","journal-title":"Neurology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/156720510793611592","volume":"7","author":"Iqbal K.","year":"2010","unstructured":"Iqbal K.; Liu F.; Gong C-X.; Grundke-Iqbal I.; Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010,7(8),656-664","journal-title":"Curr Alzheimer Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"Serrano-Pozo A.","year":"2011","unstructured":"Serrano-Pozo A.; Frosch M.P.; Masliah E.; Hyman B.T.; Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011,1(1),a006189","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0925-4439(00)00029-6","volume":"1502","author":"Serpell L.C.","year":"2000","unstructured":"Serpell L.C.; Alzheimer\u2019s amyloid fibrils: structure and assembly. Biochimica et Biophysica Acta (BBA) -. Biochim Biophys Acta Mol Basis Dis 2000,1502(1),16-30","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/0955-0674(95)80047-6","volume":"7","author":"Mandelkow E.","year":"1995","unstructured":"Mandelkow E.; Mandelkow E.M.; Microtubules and microtubule-associated proteins. Curr Opin Cell Biol 1995,7(1),72-81","journal-title":"Curr Opin Cell Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1096\/fj.11-186650","volume":"25","author":"Dumont M.","year":"2011","unstructured":"Dumont M.; Stack C.; Elipenahli C.; Jainuddin S.; Gerges M.; Starkova N.N.; Yang L.; Starkov A.A.; Beal F.; Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J 2011,25(11),4063-4072","journal-title":"FASEB J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/glia.20734","volume":"57","author":"Desai M.K.","year":"2009","unstructured":"Desai M.K.; Sudol K.L.; Janelsins M.C.; Mastrangelo M.A.; Frazer M.E.; Bowers W.J.; Triple-transgenic Alzheimer\u2019s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 2009,57(1),54-65","journal-title":"Glia"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"604658","DOI":"10.1155\/2015\/604658","volume":"2015","author":"Zuo L.","year":"2015","unstructured":"Zuo L.; Hemmelgarn B.T.; Chuang C.C.; Best T.M.; The role of oxidative stress-induced epigenetic alterations in amyloid-\u03b2 production in Alzheimer\u2019s disease. Oxid Med Cell Longev 2015,2015,604658","journal-title":"Oxid Med Cell Longev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"Braak H.","year":"1997","unstructured":"Braak H.; Braak E.; Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997,18(4),351-357","journal-title":"Neurobiol Aging"},{"key":"ref=12","unstructured":"FastStats - Leading Causes of Death. [cited 2021 Mar 26]. Available\nfrom:"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1093\/hmg\/ddp406","volume":"18","author":"Bertram L.","year":"2009","unstructured":"Bertram L.; Tanzi R.E.; Genome-wide association studies in Alzheimer\u2019s disease. Hum Mol Genet 2009,18(R2),R137-R145","journal-title":"Hum Mol Genet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2377-1-3","volume":"1","author":"Jellinger K.A.","year":"2001","unstructured":"Jellinger K.A.; Paulus W.; Wrocklage C.; Litvan I.; Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. BMC Neurol 2001,1,3","journal-title":"BMC Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ana.410340527","volume":"34","author":"Mayeux R.","year":"1993","unstructured":"Mayeux R.; Stern Y.; Ottman R.; Tatemichi T.K.; Tang M-X.; Maestre G.; Ngai C.; Tycko B.; Ginsberg H.; The apolipoprotein \u03b5 4 allele in patients with Alzheimer\u2019s disease. Ann Neurol 1993,34(5),752-754","journal-title":"Ann Neurol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a009290","volume":"146","author":"O\u2019Meara E.S.","year":"1997","unstructured":"O\u2019Meara E.S.; Kukull W.A.; Sheppard L.; Bowen J.D.; McCormick W.C.; Teri L.; Pfanschmidt M.; Thompson J.D.; Schellenberg G.D.; Larson E.B.; Head injury and risk of Alzheimer\u2019s disease by apolipoprotein E genotype. Am J Epidemiol 1997,146(5),373-384","journal-title":"Am J Epidemiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1136\/jnnp-2017-317557","volume":"90","author":"Graham N.S.N.","year":"2019","unstructured":"Graham N.S.N.; Sharp D.J.; Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia. J Neurol Neurosurg Psychiatry 2019,90(11),1221-1233","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrneurol.2017.13","volume":"13","author":"Simon D.W.","year":"2017","unstructured":"Simon D.W.; McGeachy M.J.; Baylr H.; Clark R.S.B.; Loane D.J.; Kochanek P.M.; Neuroinflammation in the evolution of secondary\ninjury, repair, and chronic neurodegeneration after traumatic\nbrain injury. Nat Rev Neurol 2017,13(3),171-191","journal-title":"Nat Rev Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"00057","DOI":"10.15406\/jnsk.2015.02.00057","volume":"2","author":"Martin W.J.","year":"2015","unstructured":"Martin W.J.; Stealth Adapted Viruses \u2013 Possible Drivers of Major Neuropsychiatric Illnesses Including Alzheimer\u2019s Disease. J Neurol Stroke 2015,2(3),00057","journal-title":"J Neurol Stroke"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/jmv.20271","volume":"75","author":"Wozniak M.A.","year":"2005","unstructured":"Wozniak M.A.; Shipley S.J.; Combrinck M.; Wilcock G.K.; Itzhaki R.F.; Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer\u2019s disease patients. J Med Virol 2005,75(2),300-306","journal-title":"J Med Virol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fnagi.2018.00224","volume":"10","author":"Fulop T.","year":"2018","unstructured":"Fulop T.; Witkowski J.M.; Bourgade K.; Khalil A.; Zerif E.; Larbi A.; Hirokawa K.; Pawelec G.; Bocti C.; Lacombe G.; Dupuis G.; Frost E.H.; Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer\u2019s disease? Front Aging Neurosci 2018,10,224","journal-title":"Front Aging Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e9505","DOI":"10.1371\/journal.pone.0009505","volume":"5","author":"Soscia S.J.","year":"2010","unstructured":"Soscia S.J.; Kirby J.E.; Washicosky K.J.; Tucker S.M.; Ingelsson M.; Hyman B.; Burton M.A.; Goldstein L.E.; Duong S.; Tanzi R.E.; Moir R.D.; The Alzheimer\u2019s disease-associated amyloid \u03b2-protein is an antimicrobial peptide. PLoS One 2010,5(3),e9505","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"92503","DOI":"10.1063\/1.4921314","volume":"5","author":"Gamez P.","year":"2015","unstructured":"Gamez P.; Caballero A.B.; Copper in Alzheimer\u2019s disease: Implications in amyloid aggregation and neurotoxicity. AIP Adv 2015,5(9),92503","journal-title":"AIP Adv"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"20466","DOI":"10.1074\/jbc.M100175200","volume":"276","author":"Curtain C.C.","year":"2001","unstructured":"Curtain C.C.; Ali F.; Volitakis I.; Cherny R.A.; Norton R.S.; Beyreuther K.; Barrow C.J.; Masters C.L.; Bush A.I.; Barnham K.J.; Alzheimer\u2019s disease amyloid-\u03b2 binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001,276(23),20466-20473","journal-title":"J Biol Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1001\/archneur.1997.00550230066019","volume":"54","author":"Evans D.A.","year":"1997","unstructured":"Evans D.A.; Hebert L.E.; Beckett L.A.; Scherr P.A.; Albert M.S.; Chown M.J.; Pilgrim D.M.; Taylor J.O.; Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol 1997,54(11),1399-1405","journal-title":"Arch Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/156720507780362047","volume":"4","author":"Whitmer R.A.","year":"2007","unstructured":"Whitmer R.A.; Gunderson E.P.; Quesenberry C.P.; Zhou J.; Yaffe K.; Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007,4(2),103-109","journal-title":"Curr Alzheimer Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1136\/bmj.38446.466238.E0","volume":"330","author":"Whitmer R.A.","year":"2005","unstructured":"Whitmer R.A.; Gunderson E.P.; Barrett-Connor E.; Quesenberry C.P.; Yaffe K.; Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005,330(7504),1360","journal-title":"BMJ"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/j.1749-6632.1997.tb48496.x","volume":"826","author":"Leibson C.L.","year":"1997","unstructured":"Leibson C.L.; Rocca W.A.; Hanson V.A.; Cha R.; Kokmen E.; O\u2019Brien P.C.; Palumbo P.J.; The risk of dementia among persons with diabetes mellitus: A population-based cohort study. Ann N Y Acad Sci 1997,826,422-427","journal-title":"Ann N Y Acad Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2147\/CIA.S74042","volume":"10","author":"Li X.","year":"2015","unstructured":"Li X.; Song D.; Leng S.X.; Link between type 2 diabetes and Alzheimer\u2019s disease: from epidemiology to mechanism and treatment. Clin Interv Aging 2015,10,549-560","journal-title":"Clin Interv Aging"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e87095","DOI":"10.1371\/journal.pone.0087095","volume":"9","author":"Huang C-C.","year":"2014","unstructured":"Huang C-C.; Chung C-M.; Leu H-B.; Lin L-Y.; Chiu C-C.; Hsu C-Y.; Chiang C.H.; Huang P.H.; Chen T.J.; Lin S.J.; Chen J.W.; Chan W.L.; Diabetes mellitus and the risk of Alzheimer\u2019s disease: a nationwide population-based study. PLoS One 2014,9(1),e87095","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/archneur.61.5.661","volume":"61","author":"Arvanitakis Z.","year":"2004","unstructured":"Arvanitakis Z.; Wilson R.S.; Bienias J.L.; Evans D.A.; Bennett D.A.; Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004,61(5),661-666","journal-title":"Arch Neurol"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12474","author":"Yassine H.N.","year":"2021","unstructured":"Yassine H.N.; Solomon V.; Thakral A.; Sheikh-Bahaei N.; Chui H.C.; Braskie M.N.; Schneider L.S.; Talbot K.; Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists. Alzheimers Dement Online ahead of print2021","journal-title":"Alzheimers Dement"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"101397","DOI":"10.1016\/j.arr.2021.101397","volume":"70","author":"Wi\u0119ckowska-Gacek A.","year":"2021","unstructured":"Wi\u0119ckowska-Gacek A.; Mietelska-Porowska A.; Wydrych M.; Wojda U.; Western diet as a trigger of Alzheimer\u2019s disease: From metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration. Ageing Res Rev 2021,70(Nov),101397","journal-title":"Ageing Res Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"E3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"Nguyen T.T.","year":"2020","unstructured":"Nguyen T.T.; Ta Q.T.H.; Nguyen T.K.O.; Nguyen T.T.D.; Giau V.V.; Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int J Mol Sci 2020,21(9),E3165","journal-title":"Int J Mol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jacc.2019.10.062","volume":"75","author":"Cortes-Canteli M.","year":"2020","unstructured":"Cortes-Canteli M.; Iadecola C.; Alzheimer\u2019s disease and vascular aging: JACC focus seminar. J Am Coll Cardiol 2020,75(8),942-951","journal-title":"J Am Coll Cardiol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/ph14090890","volume":"14","author":"Poor S.R.","year":"2021","unstructured":"Poor S.R.; Ettcheto M.; Cano A.; Sanchez-Lopez E.; Manzine P.R.; Olloquequi J.; Camins A.; Javan M.; Metformin a potential pharmacological strategy in late onset Alzheimer\u2019s disease treatment. Pharmaceuticals (Basel) 2021,14(9),890","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.nutres.2016.11.002","volume":"36","author":"Grizzanti J.","year":"2016","unstructured":"Grizzanti J.; Lee H.G.; Camins A.; Pallas M.; Casadesus G.; The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer\u2019s disease. Nutr Res 2016,36(12),1305-1315","journal-title":"Nutr Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.2337\/db12-0073","volume":"61","author":"Taylor R.","year":"2012","unstructured":"Taylor R.; Insulin resistance and type 2 diabetes. Diabetes 2012,61(4),778-779","journal-title":"Diabetes"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"453892","DOI":"10.1155\/2010\/453892","volume":"2010","author":"Kaneto H.","year":"2010","unstructured":"Kaneto H.; Katakami N.; Matsuhisa M.; Matsuoka T.A.; Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm 2010,2010,453892","journal-title":"Mediators Inflamm"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev-biochem-072909-095555","volume":"81","author":"Back S.H.","year":"2012","unstructured":"Back S.H.; Kaufman R.J.; Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem 2012,81,767-793","journal-title":"Annu Rev Biochem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diabetes.52.1.1","volume":"52","author":"Evans J.L.","year":"2003","unstructured":"Evans J.L.; Goldfine I.D.; Maddux B.A.; Grodsky G.M.; Are oxidative stress-activated signaling pathways mediators of insulin resistance and \u03b2-cell dysfunction? Diabetes 2003,52(1),1-8","journal-title":"Diabetes"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diacare.13.2.S77","volume":"13","author":"Schwartz R.S.","year":"1990","unstructured":"Schwartz R.S.; Exercise training in treatment of diabetes mellitus in elderly patients. Diabetes Care 1990,13(Suppl. 2),77-85","journal-title":"Diabetes Care"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1212\/WNL.0000000000001982","volume":"85","author":"Moran C.","year":"2015","unstructured":"Moran C.; Beare R.; Phan T.G.; Bruce D.G.; Callisaya M.L.; Srikanth V.; Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology 2015,85(13),1123-1130","journal-title":"Neurology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/gt.2013.85","volume":"21","author":"P\u00e9rez-Gonz\u00e1lez R.","year":"2014","unstructured":"P\u00e9rez-Gonz\u00e1lez R.; Alvira-Botero M.X.; Robayo O.; Antequera D.; Garz\u00f3n M.; Mart\u00edn-Moreno A.M.; Brera B.; de Ceballos M.L.; Carro E.; Leptin gene therapy attenuates neuronal damages evoked by amyloid-\u03b2 and rescues memory deficits in APP\/PS1 mice. Gene Ther 2014,21(3),298-308","journal-title":"Gene Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jns.2016.04.017","volume":"365","author":"Wennberg A.M.V.","year":"2016","unstructured":"Wennberg A.M.V.; Spira A.P.; Pettigrew C.; Soldan A.; Zipunnikov V.; Rebok G.W.; Roses A.D.; Lutz M.W.; Miller M.M.; Thambisetty M.; Albert M.S.; Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. J Neurol Sci 2016,365,89-95","journal-title":"J Neurol Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/1872214811307020009","volume":"7","author":"Dash S.K.","year":"2013","unstructured":"Dash S.K.; Cognitive impairment and diabetes. Recent Pat Endocr Metab Immune Drug Discov 2013,7(2),155-165","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S2213-8587(13)70088-3","volume":"2","author":"Biessels G.J.","year":"2014","unstructured":"Biessels G.J.; Strachan M.W.J.; Visseren F.L.J.; Kappelle L.J.; Whitmer R.A.; Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol 2014,2(3),246-255","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.2337\/diabetes.51.10.2944","volume":"51","author":"Kelley D.E.","year":"2002","unstructured":"Kelley D.E.; He J.; Menshikova E.V.; Ritov V.B.; Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002,51(10),2944-2950","journal-title":"Diabetes"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"Mootha V.K.","year":"2003","unstructured":"Mootha V.K.; Lindgren C.M.; Eriksson K-F.; Subramanian A.; Sihag S.; Lehar J.; Puigserver P.; Carlsson E.; Ridderstr\u00e5le M.; Laurila E.; Houstis N.; Daly M.J.; Patterson N.; Mesirov J.P.; Golub T.R.; Tamayo P.; Spiegelman B.; Lander E.S.; Hirschhorn J.N.; Altshuler D.; Groop L.C.; PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003,34(3),267-273","journal-title":"Nat Genet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"8466","DOI":"10.1073\/pnas.1032913100","volume":"100","author":"Patti M.E.","year":"2003","unstructured":"Patti M.E.; Butte A.J.; Crunkhorn S.; Cusi K.; Berria R.; Kashyap S.; Miyazaki Y.; Kohane I.; Costello M.; Saccone R.; Landaker E.J.; Goldfine A.B.; Mun E.; DeFronzo R.; Finlayson J.; Kahn C.R.; Mandarino L.J.; Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003,100(14),8466-8471","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00005-012-0210-1","volume":"61","author":"Wieser V.","year":"2013","unstructured":"Wieser V.; Moschen A.R.; Tilg H.; Inflammation, cytokines and insulin resistance: A clinical perspective. Arch Immunol Ther Exp (Warsz) 2013,61(2),119-125","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/jcm8091385","volume":"8","author":"Burgos-Mor\u00f3n E.","year":"2019","unstructured":"Burgos-Mor\u00f3n E.; Abad-Jim\u00e9nez Z.; Mara\u00f1\u00f3n A.M.; Iannantuoni F.; Escribano-L\u00f3pez I.; L\u00f3pez-Dom\u00e8nech S.; Salom C.; Jover A.; Mora V.; Roldan I.; Sol\u00e1 E.; Rocha M.; V\u00edctor V.M.; Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: The battle continues. J Clin Med 2019,8(9),1385","journal-title":"J Clin Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3810\/pgm.2012.07.2577","volume":"124","author":"Hasnain M.","year":"2012","unstructured":"Hasnain M.; Vieweg W.V.R.; Hollett B.; Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 2012,124(4),154-167","journal-title":"Postgrad Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00125-012-2762-3","volume":"56","author":"Eizirik D.L.","year":"2013","unstructured":"Eizirik D.L.; Miani M.; Cardozo A.K.; Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia 2013,56(2),234-241","journal-title":"Diabetologia"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1038\/s41598-020-60664-5","volume":"10","author":"Mousa Y.M.","year":"2020","unstructured":"Mousa Y.M.; Abdallah I.M.; Hwang M.; Martin D.R.; Kaddoumi A.; Amylin and pramlintide modulate \u03b3-secretase level and APP processing in lipid rafts. Sci Rep 2020,10(1),3751","journal-title":"Sci Rep"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"10942","DOI":"10.1038\/s41598-019-47255-9","volume":"9","author":"Soudy R.","year":"2019","unstructured":"Soudy R.; Kimura R.; Patel A.; Fu W.; Kaur K.; Westaway D.; Yang J.; Jhamandas J.; Short amylin receptor antagonist peptides improve memory deficits in Alzheimer\u2019s disease mouse model. Sci Rep 2019,9(1),10942","journal-title":"Sci Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.tips.2011.05.007","volume":"32","author":"Archbold J.K.","year":"2011","unstructured":"Archbold J.K.; Flanagan J.U.; Watkins H.A.; Gingell J.J.; Hay D.L.; Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol Sci 2011,32(10),591-600","journal-title":"Trends Pharmacol Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1042\/BST0320865","volume":"32","author":"Hay D.L.","year":"2004","unstructured":"Hay D.L.; Christopoulos G.; Christopoulos A.; Sexton P.M.; Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans 2004,32(Pt 5),865-867","journal-title":"Biochem Soc Trans"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/0306-4522(94)90388-3","volume":"62","author":"Sexton P.M.","year":"1994","unstructured":"Sexton P.M.; Paxinos G.; Kenney M.A.; Wookey P.J.; Beaumont K.; In vitro\nautoradiographic localization of amylin binding sites in rat brain.\n Neuroscience 1994,62(2),553-567","journal-title":"Neuroscience"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.bone.2008.07.003","volume":"43","author":"Naot D.","year":"2008","unstructured":"Naot D.; Cornish J.; The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone 2008,43(5),813-818","journal-title":"Bone"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0006-291X(86)90708-4","volume":"140","author":"Westermark P.","year":"1986","unstructured":"Westermark P.; Wernstedt C.; Wilander E.; Sletten K.; A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986,140(3),827-831","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF00500385","volume":"34","author":"Sanke T.","year":"1991","unstructured":"Sanke T.; Hanabusa T.; Nakano Y.; Oki C.; Okai K.; Nishimura S.; Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991,34(2),129-132","journal-title":"Diabetologia"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1042\/bst0230325","volume":"23","author":"Young A.","year":"1995","unstructured":"Young A.; Pittner R.; Gedulin B.; Vine W.; Rink T.; Amylin regulation of carbohydrate metabolism. Biochem Soc Trans 1995,23(2),325-331","journal-title":"Biochem Soc Trans"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S1054-3589(05)52005-2","volume":"52","author":"Young A.","year":"2005","unstructured":"Young A.; Inhibition of food intake. Adv Pharmacol 2005,52,79-98","journal-title":"Adv Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","volume":"46","author":"Gedulin B.R.","year":"1997","unstructured":"Gedulin B.R.; Rink T.J.; Young A.A.; Dose-response for glucagonostatic effect of amylin in rats. Metabolism 1997,46(1),67-70","journal-title":"Metabolism"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"R1395","DOI":"10.1152\/ajpregu.00597.2001","volume":"282","author":"Reidelberger R.D.","year":"2002","unstructured":"Reidelberger R.D.; Kelsey L.; Heimann D.; Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 2002,282(5),R1395-R1404","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2337\/diab.42.2.330","volume":"42","author":"Wang Z-L.","year":"1993","unstructured":"Wang Z-L.; Bennet W.M.; Ghatei M.A.; Byfield P.G.H.; Smith D.M.; Bloom S.R.; Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 1993,42(2),330-335","journal-title":"Diabetes"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/0006-8993(91)91644-G","volume":"539","author":"Chance W.T.","year":"1991","unstructured":"Chance W.T.; Balasubramaniam A.; Zhang F.S.; Wimalawansa S.J.; Fischer J.E.; Anorexia following the intrahypothalamic administration of amylin. Brain Res 1991,539(2),352-354","journal-title":"Brain Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cmet.2008.01.007","volume":"7","author":"Mesaros A.","year":"2008","unstructured":"Mesaros A.; Koralov S.B.; Rother E.; Wunderlich F.T.; Ernst M.B.; Barsh G.S.; Rajewsky K.; Br\u00fcning J.C.; Activation of Stat3 signaling in AgRP neurons promotes locomotor activity. Cell Metab 2008,7(3),236-248","journal-title":"Cell Metab"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1210\/en.2009-0546","volume":"151","author":"Turek V.F.","year":"2010","unstructured":"Turek V.F.; Trevaskis J.L.; Levin B.E.; Dunn-Meynell A.A.; Irani B.; Gu G.; Wittmer C.; Griffin P.S.; Vu C.; Parkes D.G.; Roth J.D.; Mechanisms of amylin\/leptin synergy in rodent models. Endocrinology 2010,151(1),143-152","journal-title":"Endocrinology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.peptides.2007.06.011","volume":"28","author":"Olsson M.","year":"2007","unstructured":"Olsson M.; Herrington M.K.; Reidelberger R.D.; Permert J.; Arnelo U.; Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat. Peptides 2007,28(7),1416-1423","journal-title":"Peptides"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0196-9781(02)00288-7","volume":"24","author":"Mollet A.","year":"2003","unstructured":"Mollet A.; Meier S.; Riediger T.; Lutz T.A.; Histamine H1 receptors in the ventromedial hypothalamus mediate the anorectic action of the pancreatic hormone amylin. Peptides 2003,24(1),155-158","journal-title":"Peptides"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1006\/bbrc.1998.9308","volume":"250","author":"Gebre-Medhin S.","year":"1998","unstructured":"Gebre-Medhin S.; Mulder H.; Pekny M.; Westermark G.; T\u00f6rnell J.; Westermark P.; Sundler F.; Ahr\u00e9n B.; Betsholtz C.; Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 1998,250(2),271-277","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1124\/mol.56.1.235","volume":"56","author":"Christopoulos G.","year":"1999","unstructured":"Christopoulos G.; Perry K.J.; Morfis M.; Tilakaratne N.; Gao Y.; Fraser N.J.; Main M.J.; Foord S.M.; Sexton P.M.; Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999,56(1),235-242","journal-title":"Mol Pharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-4614-2364-5_2","volume":"744","author":"Barwell J.","year":"2012","unstructured":"Barwell J.; Wootten D.; Simms J.; Hay D.L.; Poyner D.R.; RAMPs and CGRP receptors. Adv Exp Med Biol 2012,744,13-24","journal-title":"Adv Exp Med Biol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1210\/endo.140.6.6930","volume":"140","author":"Muff R.","year":"1999","unstructured":"Muff R.; B\u00fchlmann N.; Fischer J.A.; Born W.; An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 1999,140(6),2924-2927","journal-title":"Endocrinology"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1042\/bj3510347","volume":"351","author":"Leuth\u00e4user K.","year":"2000","unstructured":"Leuth\u00e4user K.; Gujer R.; Aldecoa A.; McKinney R.A.; Muff R.; Fischer J.A.; Born W.; Receptor-activity-modifying protein 1\nforms heterodimers with two G-protein-coupled receptors to define\nligand recognition. Biochem J 2000,351(Pt 2),347-351","journal-title":"Biochem J"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.027953","author":"Hay D.L.","year":"2006","unstructured":"Hay D.L.; Christopoulos G.; Christopoulos A.; Sexton P.M.;  Determinants of BIBN4096BS affinity for CGRP and amylin receptors; the role of RAMP1 2006","journal-title":"Determinants of BIBN4096BS affinity for CGRP and amylin receptors; the role of RAMP1"},{"key":"ref=79","first-page":"493","volume":"44","author":"Beaumont K.","year":"1993","unstructured":"Beaumont K.; Kenney M.A.; Young A.A.; Rink T.J.; High affinity\namylin binding sites in rat brain. Mol Pharmacol 1993,44(3),493-497","journal-title":"Mol Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/0306-4522(95)00322-A","volume":"69","author":"Hilton J.M.","year":"1995","unstructured":"Hilton J.M.; Chai S.Y.; Sexton P.M.; In vitro\nautoradiographic localization of the calcitonin receptor isoforms, C1a and C1b, in rat brain.\n Neuroscience 1995,69(4),1223-1237","journal-title":"Neuroscience"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1124\/pr.54.2.233","volume":"54","author":"Poyner D.R.","year":"2002","unstructured":"Poyner D.R.; Sexton P.M.; Marshall I.; Smith D.M.; Quirion R.; Born W.; Muff R.; Fischer J.A.; Foord S.M.; International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002,54(2),233-246","journal-title":"Pharmacol Rev"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0303-7207(00)00212-4","volume":"162","author":"Husmann K.","year":"2000","unstructured":"Husmann K.; Sexton P.M.; Fischer J.A.; Born W.; Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function. Mol Cell Endocrinol 2000,162(1-2),35-43","journal-title":"Mol Cell Endocrinol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1139\/y95-146","volume":"73","author":"Christopoulos G.","year":"1995","unstructured":"Christopoulos G.; Paxinos G.; Huang X.F.; Beaumont K.; Toga A.W.; Sexton P.M.; Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol 1995,73(7),1037-1041","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"14731","DOI":"10.1074\/jbc.M112084200","volume":"277","author":"Flahaut M.","year":"2002","unstructured":"Flahaut M.; Rossier B.C.; Firsov D.; Respective roles of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying proteins (RAMP) in cell surface expression of CRLR\/RAMP heterodimeric receptors. J Biol Chem 2002,277(17),14731-14737","journal-title":"J Biol Chem"},{"key":"ref=85","first-page":"906","volume":"130","author":"Bhogal R.","year":"1992","unstructured":"Bhogal R.; Smith D.M.; Bloom S.R.; Investigation and characterization\nof binding sites for islet amyloid polypeptide in rat membranes. Endocrinology 1992,130(2),906-913","journal-title":"Endocrinology"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0006-8993(83)90334-7","volume":"265","author":"Olgiati V.R.","year":"1983","unstructured":"Olgiati V.R.; Guidobono F.; Netti C.; Pecile A.; Localization of calcitonin binding sites in rat central nervous system: evidence of its neuroactivity. Brain Res 1983,265(2),209-215","journal-title":"Brain Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0014-5793(00)02097-4","volume":"483","author":"Nakamoto H.","year":"2000","unstructured":"Nakamoto H.; Suzuki N.; Roy S.K.; Constitutive expression of a small heat-shock protein confers cellular thermotolerance and thermal protection to the photosynthetic apparatus in cyanobacteria. FEBS Lett 2000,483(2-3),169-174","journal-title":"FEBS Lett"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0169-328X(01)00179-6","volume":"93","author":"Ueda T.","year":"2001","unstructured":"Ueda T.; Ugawa S.; Saishin Y.; Shimada S.; Expression of receptor-activity modifying protein (RAMP) mRNAs in the mouse brain. Brain Res Mol Brain Res 2001,93(1),36-45","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1046\/j.1365-2826.2003.01064.x","volume":"15","author":"Stachniak T.J.E.","year":"2003","unstructured":"Stachniak T.J.E.; Krukoff T.L.; Receptor activity modifying protein 2 distribution in the rat central nervous system and regulation by changes in blood pressure. J Neuroendocrinol 2003,15(9),840-850","journal-title":"J Neuroendocrinol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.brainres.2003.10.040","volume":"997","author":"Barth S.W.","year":"2004","unstructured":"Barth S.W.; Riediger T.; Lutz T.A.; Rechkemmer G.; Peripheral amylin activates circumventricular organs expressing calcitonin receptor a\/b subtypes and receptor-activity modifying proteins in the rat. Brain Res 2004,997(1),97-102","journal-title":"Brain Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.brainres.2004.10.012","volume":"1030","author":"Becskei C.","year":"2004","unstructured":"Becskei C.; Riediger T.; Z\u00fcnd D.; Wookey P.; Lutz T.A.; Immunohistochemical mapping of calcitonin receptors in the adult rat brain. Brain Res 2004,1030(2),221-233","journal-title":"Brain Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/0024-3205(95)02197-Q","volume":"57","author":"Banks W.A.","year":"1995","unstructured":"Banks W.A.; Kastin A.J.; Maness L.M.; Huang W.; Jaspan J.B.; Permeability of the blood-brain barrier to amylin. Life Sci 1995,57(22),1993-2001","journal-title":"Life Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2337\/db14-0645","volume":"64","author":"Le Foll C.","year":"2015","unstructured":"Le Foll C.; Johnson M.D.; Dunn-Meynell A.A.; Boyle C.N.; Lutz T.A.; Levin B.E.; Amylin-induced central IL-6 production enhances ventromedial hypothalamic leptin signaling. Diabetes 2015,64(5),1621-1631","journal-title":"Diabetes"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/npp.2013.66","volume":"38","author":"Mietlicki-Baase E.G.","year":"2013","unstructured":"Mietlicki-Baase E.G.; Rupprecht L.E.; Olivos D.R.; Zimmer D.J.; Alter M.D.; Pierce R.C.; Schmidt H.D.; Hayes M.R.; Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake. Neuropsychopharmacology 2013,38(9),1685-1697","journal-title":"Neuropsychopharmacology"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1111\/bph.13496","volume":"173","author":"Bower R.L.","year":"2016","unstructured":"Bower R.L.; Hay D.L.; Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development. Br J Pharmacol 2016,173(12),1883-1898","journal-title":"Br J Pharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1074\/jbc.C200629200","volume":"278","author":"Christopoulos A.","year":"2003","unstructured":"Christopoulos A.; Christopoulos G.; Morfis M.; Udawela M.; Laburthe M.; Couvineau A.; Kuwasako K.; Tilakaratne N.; Sexton P.M.; Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 2003,278(5),3293-3297","journal-title":"J Biol Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.peptides.2009.12.016","volume":"31","author":"Bailey R.J.","year":"2010","unstructured":"Bailey R.J.; Bradley J.W.I.; Poyner D.R.; Rathbone D.L.; Hay D.L.; Functional characterization of two human receptor activity-modifying protein 3 variants. Peptides 2010,31(4),579-584","journal-title":"Peptides"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"R340","DOI":"10.1152\/ajpregu.00380.2011","volume":"302","author":"Potes C.S.","year":"2012","unstructured":"Potes C.S.; Boyle C.N.; Wookey P.J.; Riediger T.; Lutz T.A.; Involvement of the extracellular signal-regulated kinase 1\/2 signaling pathway in amylin\u2019s eating inhibitory effect. Am J Physiol Regul Integr Comp Physiol 2012,302(3),R340-R351","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neuroscience.2019.11.036","volume":"447","author":"Coester B.","year":"2020","unstructured":"Coester B.; Pence S.W.; Arrigoni S.; Boyle C.N.; Le Foll C.; Lutz T.A.; RAMP1 and RAMP3 differentially control amylin\u2019s effects on food intake, glucose and energy balance in male and female mice. Neuroscience 2020,447,74-93","journal-title":"Neuroscience"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1210\/en.2007-1735","volume":"149","author":"Morfis M.","year":"2008","unstructured":"Morfis M.; Tilakaratne N.; Furness S.G.B.; Christopoulos G.; Werry T.D.; Christopoulos A.; Sexton P.M.; Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology 2008,149(11),5423-5431","journal-title":"Endocrinology"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1083\/jcb.200312135","volume":"164","author":"Dacquin R.","year":"2004","unstructured":"Dacquin R.; Davey R.A.; Laplace C.; Levasseur R.; Morris H.A.; Goldring S.R.; Gebre-Medhin S.; Galson D.L.; Zajac J.D.; Karsenty G.; \nAmylin inhibits bone resorption while the calcitonin receptor controls bone formation \nin vivo\n.\n J Cell Biol 2004,164(4),509-514","journal-title":"J Cell Biol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1021\/bm401406e","volume":"15","author":"Qi R.","year":"2014","unstructured":"Qi R.; Luo Y.; Ma B.; Nussinov R.; Wei G.; Conformational distribution and \u03b1-helix to \u03b2-sheet transition of human amylin fragment dimer. Biomacromolecules 2014,15(1),122-131","journal-title":"Biomacromolecules"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1210\/en.2013-1658","volume":"155","author":"Gingell J.J.","year":"2014","unstructured":"Gingell J.J.; Burns E.R.; Hay D.L.; Activity of pramlintide, rat and human amylin but not A\u03b21-42 at human amylin receptors. Endocrinology 2014,155(1),21-26","journal-title":"Endocrinology"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bph.14075","volume":"175","author":"Hay D.L.","year":"2018","unstructured":"Hay D.L.; Garelja M.L.; Poyner D.R.; Walker C.S.; Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol 2018,175(1),3-17","journal-title":"Br J Pharmacol"},{"key":"ref=105","unstructured":"Amylin: Physiology and Pharmacology - Andrew Young - Google\nBooks. Available from:"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.2337\/dc07-0649","volume":"30","author":"Banks W.A.","year":"2007","unstructured":"Banks W.A.; Willoughby L.M.; Thomas D.R.; Morley J.E.; Insulin resistance syndrome in the elderly: assessment of functional, biochemical, metabolic, and inflammatory status. Diabetes Care 2007,30(9),2369-2373","journal-title":"Diabetes Care"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1476-5381.2011.01717.x","volume":"166","author":"Bailey R.J.","year":"2012","unstructured":"Bailey R.J.; Walker C.S.; Ferner A.H.; Loomes K.M.; Prijic G.; Halim A.; Whiting L.; Phillips A.R.; Hay D.L.; Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br J Pharmacol 2012,166(1),151-167","journal-title":"Br J Pharmacol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/ijo.2009.13","volume":"33","author":"Lutz T.A.","year":"2009","unstructured":"Lutz T.A.; Control of food intake and energy expenditure by amylin-therapeutic implications. Int J Obes 2009,33(S1)(Suppl. 1),S24-S27","journal-title":"Int J Obes"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.tem.2010.03.006","volume":"21","author":"Trevaskis J.L.","year":"2010","unstructured":"Trevaskis J.L.; Parkes D.G.; Roth J.D.; Insights into amylin-leptin synergy. Trends Endocrinol Metab 2010,21(8),473-479","journal-title":"Trends Endocrinol Metab"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"R1697","DOI":"10.1152\/ajpregu.2001.280.6.R1697","volume":"280","author":"Lutz T.A.","year":"2001","unstructured":"Lutz T.A.; Tschudy S.; Mollet A.; Geary N.; Scharrer E.; Dopamine D(2) receptors mediate amylin\u2019s acute satiety effect. Am J Physiol Regul Integr Comp Physiol 2001,280(6),R1697-R1703","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MED.0b013e32835b896f","volume":"20","author":"Roth J.D.","year":"2013","unstructured":"Roth J.D.; Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology. Curr Opin Endocrinol Diabetes Obes 2013,20(1),8-13","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref=112","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00066.2005","author":"Geary N.","year":"2005","unstructured":"Geary N.; A new way of looking at eating. Am J Physiol 2005","journal-title":"Am J Physiol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.physbeh.2004.01.006","volume":"81","author":"Mollet A.","year":"2004","unstructured":"Mollet A.; Gilg S.; Riediger T.; Lutz T.A.; Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats. Physiol Behav 2004,81(1),149-155","journal-title":"Physiol Behav"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.regpep.2006.06.004","volume":"137","author":"Gedulin B.R.","year":"2006","unstructured":"Gedulin B.R.; Jodka C.M.; Herrmann K.; Young A.A.; Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul Pept 2006,137(3),121-127","journal-title":"Regul Pept"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1210\/endo.142.11.8593","volume":"142","author":"Rushing P.A.","year":"2001","unstructured":"Rushing P.A.; Hagan M.M.; Seeley R.J.; Lutz T.A.; D\u2019Alessio D.A.; Air E.L.; Woods S.C.; Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 2001,142(11),5035-5038","journal-title":"Endocrinology"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0196-9781(96)00062-9","volume":"17","author":"Clementi G.","year":"1996","unstructured":"Clementi G.; Valerio C.; Emmi I.; Prato A.; Drago F.; Behavioral effects of amylin injected intracerebroventricularly in the rat. Peptides 1996,17(4),589-591","journal-title":"Peptides"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/ejn.13163","volume":"43","author":"Liberini C.G.","year":"2016","unstructured":"Liberini C.G.; Boyle C.N.; Cifani C.; Venniro M.; Hope B.T.; Lutz T.A.; Amylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons. Eur J Neurosci 2016,43(5),653-661","journal-title":"Eur J Neurosci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2337\/db10-0692","volume":"60","author":"Zhang Z.","year":"2011","unstructured":"Zhang Z.; Liu X.; Morgan D.A.; Kuburas A.; Thedens D.R.; Russo A.F.; Rahmouni K.; Neuronal receptor activity-modifying protein 1 promotes energy expenditure in mice. Diabetes 2011,60(4),1063-1071","journal-title":"Diabetes"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2337\/db17-1347","volume":"67","author":"Lutz T.A.","year":"2018","unstructured":"Lutz T.A.; Coester B.; Whiting L.; Dunn-Meynell A.A.; Boyle C.N.; Bouret S.G.; Levin B.E.; Le Foll C.; Amylin Selectively Signals Onto POMC Neurons in the Arcuate Nucleus of the Hypothalamus. Diabetes 2018,67(5),805-817","journal-title":"Diabetes"},{"key":"ref=120","first-page":"1113","volume":"297","author":"Banks W.A.","year":"2001","unstructured":"Banks W.A.; Farr S.A.; Butt W.; Kumar V.B.; Franko M.W.; Morley J.E.; Delivery across the blood-brain barrier of antisense directed\nagainst amyloid beta: reversal of learning and memory deficits\nin mice overexpressing amyloid precursor protein. J Pharmacol Exp Ther 2001,297(3),1113-1121","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1210\/en.2006-0393","volume":"147","author":"Roth J.D.","year":"2006","unstructured":"Roth J.D.; Hughes H.; Kendall E.; Baron A.D.; Anderson C.M.; Antiobesity effects of the \u03b2-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 2006,147(12),5855-5864","journal-title":"Endocrinology"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"R1855","DOI":"10.1152\/ajpregu.00297.2007","volume":"293","author":"Mack C.","year":"2007","unstructured":"Mack C.; Wilson J.; Athanacio J.; Reynolds J.; Laugero K.; Guss S.; Vu C.; Roth J.; Parkes D.; Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol 2007,293(5),R1855-R1863","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.2337\/dc07-0589","volume":"30","author":"Riddle M.","year":"2007","unstructured":"Riddle M.; Frias J.; Zhang B.; Maier H.; Brown C.; Lutz K.; Kolterman O.; Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007,30(11),2794-2799","journal-title":"Diabetes Care"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.2337\/db19-0849","volume":"69","author":"Coester B.","year":"2020","unstructured":"Coester B.; Koester-Hegmann C.; Lutz T.A.; Le Foll C.; Amylin\/Calcitonin Receptor-Mediated Signaling in POMC Neurons Influences Energy Balance and Locomotor Activity in Chow-Fed Male Mice. Diabetes 2020,69(6),1110-1125","journal-title":"Diabetes"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.brainres.2010.01.027","volume":"1350","author":"Roth J.D.","year":"2010","unstructured":"Roth J.D.; Trevaskis J.L.; Turek V.F.; Parkes D.G.; \u201cWeighing in\u201d on synergy: preclinical research on neurohormonal anti-obesity combinations. Brain Res 2010,1350,86-94","journal-title":"Brain Res"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"11582","DOI":"10.1523\/JNEUROSCI.5712-08.2009","volume":"29","author":"Ernst M.B.","year":"2009","unstructured":"Ernst M.B.; Wunderlich C.M.; Hess S.; Paehler M.; Mesaros A.; Koralov S.B.; Kleinridders A.; Husch A.; M\u00fcnzberg H.; Hampel B.; Alber J.; Kloppenburg P.; Br\u00fcning J.C.; Wunderlich F.T.; Enhanced Stat3 activation in POMC neurons provokes negative feedback inhibition of leptin and insulin signaling in obesity. J Neurosci 2009,29(37),11582-11593","journal-title":"J Neurosci"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0024-3205(96)00370-0","volume":"59","author":"Schi\u00f6th H.B.","year":"1996","unstructured":"Schi\u00f6th H.B.; Chhajlani V.; Muceniece R.; Klusa V.; Wikberg J.E.S.; Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. Life Sci 1996,59(10),797-801","journal-title":"Life Sci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0196-9781(97)00078-8","volume":"18","author":"Adan R.A.H.","year":"1997","unstructured":"Adan R.A.H.; Gispen W.H.; Brain melanocortin receptors: from cloning to function. Peptides 1997,18(8),1279-1287","journal-title":"Peptides"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1113\/jphysiol.2002.018671","volume":"541","author":"Eiden S.","year":"2002","unstructured":"Eiden S.; Daniel C.; Steinbrueck A.; Schmidt I.; Simon E.; Salmon calcitonin - a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents. J Physiol 2002,541(Pt 3),1041-1048","journal-title":"J Physiol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","volume":"84","author":"Cooper G.J.","year":"1987","unstructured":"Cooper G.J.; Willis A.C.; Clark A.; Turner R.C.; Sim R.B.; Reid K.B.; Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987,84(23),8628-8632","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=131","first-page":"414","volume":"127","author":"Westermark P.","year":"1987","unstructured":"Westermark P.; Wernstedt C.; O\u2019Brien T.D.; Hayden D.W.; Johnson K.H.; Islet amyloid in type 2 human diabetes mellitus and\nadult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 1987,127(3),414-417","journal-title":"Am J Pathol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/JAD-160047","volume":"53","author":"Verma N.","year":"2016","unstructured":"Verma N.; Ly H.; Liu M.; Chen J.; Zhu H.; Chow M.; Hersh L.B.; Despa F.; Intraneuronal amylin deposition, peroxidative membrane injury and increased IL-1\u03b2 synthesis in brains of Alzheimer\u2019s disease patients with type-2 diabetes and in diabetic HIP rats. J Alzheimers Dis 2016,53(1),259-272","journal-title":"J Alzheimers Dis"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"e12130","DOI":"10.1002\/trc2.12130","volume":"7","author":"Ly H.","year":"2021","unstructured":"Ly H.; Verma N.; Sharma S.; Kotiya D.; Despa S.; Abner E.L.; Nelson P.T.; Jicha G.A.; Wilcock D.M.; Goldstein L.B.; Guerreiro R.; Br\u00e1s J.; Hanson A.J.; Craft S.; Murray A.J.; Biessels G.J.; Troakes C.; Zetterberg H.; Hardy J.; Lashley T.; Aesg; Despa, F. The association of circulating amylin with \u03b2-amyloid in familial Alzheimer\u2019s disease. Alzheimers Dement (N Y) 2021,7(1),e12130","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.23956","volume":"74","author":"Jackson K.","year":"2013","unstructured":"Jackson K.; Barisone G.A.; Diaz E.; Jin L.W.; DeCarli C.; Despa F.; Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann Neurol 2013,74(4),517-526","journal-title":"Ann Neurol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/368756a0","volume":"368","author":"Lorenzo A.","year":"1994","unstructured":"Lorenzo A.; Razzaboni B.; Weir G.C.; Yankner B.A.; Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994,368(6473),756-760","journal-title":"Nature"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41598-020-66602-9","author":"Bharadwaj P.","year":"2020","unstructured":"Bharadwaj P.; Solomon T.; Sahoo B.R.; Ignasiak K.; Gaskin S.; Rowles J.; Verdile G.; Howard M.J.; Bond C.S.; Ramamoorthy A.; Martins R.N.; Newsholme P.; Amylin and beta amyloid proteins interact to form amorphous heterocomplexes with enhanced toxicity in neuronal cells. Sci Rep 2020,10","journal-title":"Sci Rep"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.febslet.2008.05.006","volume":"582","author":"Lim Y.A.","year":"2008","unstructured":"Lim Y.A.; Ittner L.M.; Lim Y.L.; G\u00f6tz J.; Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett 2008,582(15),2188-2194","journal-title":"FEBS Lett"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1039\/c0cc01175d","volume":"46","author":"Lim S.","year":"2010","unstructured":"Lim S.; Paterson B.M.; Fodero-Tavoletti M.T.; O\u2019Keefe G.J.; Cappai R.; Barnham K.J.; Villemagne V.L.; Donnelly P.S.; A copper radiopharmaceutical for diagnostic imaging of Alzheimer\u2019s disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-\u03b2 plaques. Chem Commun (Camb) 2010,46(30),5437-5439","journal-title":"Chem Commun (Camb)"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.neurobiolaging.2013.10.076","volume":"35","author":"Adler B.L.","year":"2014","unstructured":"Adler B.L.; Yarchoan M.; Hwang H.M.; Louneva N.; Blair J.A.; Palm R.; Smith M.A.; Lee H.G.; Arnold S.E.; Casadesus G.; Neuroprotective effects of the amylin analogue pramlintide on Alzheimer\u2019s disease pathogenesis and cognition. Neurobiol Aging 2014,35(4),793-801","journal-title":"Neurobiol Aging"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3233\/JAD-140210","volume":"42","author":"Qiu W.Q.","year":"2014","unstructured":"Qiu W.Q.; Au R.; Zhu H.; Wallack M.; Liebson E.; Li H.; Rosenzweig J.; Mwamburi M.; Stern R.A.; Positive association between plasma amylin and cognition in a homebound elderly population. J Alzheimers Dis 2014,42(2),555-563","journal-title":"J Alzheimers Dis"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fnagi.2014.00186","volume":"6","author":"Qiu W.Q.","year":"2014","unstructured":"Qiu W.Q.; Zhu H.; Amylin and its analogs: a friend or foe for the treatment of Alzheimer\u2019s disease? Front Aging Neurosci 2014,6(JUL),186","journal-title":"Front Aging Neurosci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"e199826","DOI":"10.1001\/jamanetworkopen.2019.9826","volume":"2","author":"Zhu H.","year":"2019","unstructured":"Zhu H.; Tao Q.; Ang T.F.A.; Massaro J.; Gan Q.; Salim S.; Zhu R.Y.; Kolachalama V.B.; Zhang X.; Devine S.; Auerbach S.H.; DeCarli C.; Au R.; Qiu W.Q.; Association of plasma amylin concentration with Alzheimer disease and brain structure in older adults. JAMA Netw Open 2019,2(8),e199826-e199826","journal-title":"JAMA Netw Open"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1111\/j.1471-4159.1993.tb07480.x","volume":"61","author":"May P.C.","year":"1993","unstructured":"May P.C.; Boggs L.N.; Fuson K.S.; Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer\u2019s disease amyloid-\u03b2 neurotoxicity. J Neurochem 1993,61(6),2330-2333","journal-title":"J Neurochem"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.clinthera.2005.10.009","volume":"27","author":"Ryan G.J.","year":"2005","unstructured":"Ryan G.J.; Jobe L.J.; Martin R.; Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2005,27(10),1500-1512","journal-title":"Clin Ther"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","volume":"48","author":"Nyholm B.","year":"1999","unstructured":"Nyholm B.; \u00d8rskov L.; Hove K.Y.; Gravholt C.H.; M\u00f8ller N.; Alberti K.G.; Moyses C.; Kolterman O.; Schmitz O.; The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 1999,48(7),935-941","journal-title":"Metabolism"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2337\/dc09-0395","volume":"32","author":"Riddle M.","year":"2009","unstructured":"Riddle M.; Pencek R.; Charenkavanich S.; Lutz K.; Wilhelm K.; Porter L.; Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009,32(9),1577-1582","journal-title":"Diabetes Care"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.nbd.2006.08.017","volume":"24","author":"Garcia-Alloza M.","year":"2006","unstructured":"Garcia-Alloza M.; Robbins E.M.; Zhang-Nunes S.X.; Purcell S.M.; Betensky R.A.; Raju S.; Prada C.; Greenberg S.M.; Bacskai B.J.; Frosch M.P.; Characterization of amyloid deposition in the APPswe\/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006,24(3),516-524","journal-title":"Neurobiol Dis"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JAD-180421","volume":"69","author":"Patrick S.","year":"2019","unstructured":"Patrick S.; Corrigan R.; Grizzanti J.; Mey M.; Blair J.; Pallas M.; Camins A.; Lee H.G.; Casadesus G.; Neuroprotective effects of the amylin analog, pramlintide, on Alzheimer\u2019s disease are associated with oxidative stress regulation mechanisms. J Alzheimers Dis 2019,69(1),157-168","journal-title":"J Alzheimers Dis"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/mp.2014.17","volume":"20","author":"Zhu H.","year":"2015","unstructured":"Zhu H.; Wang X.; Wallack M.; Li H.; Carreras I.; Dedeoglu A.; Hur J.Y.; Zheng H.; Li H.; Fine R.; Mwamburi M.; Sun X.; Kowall N.; Stern R.A.; Qiu W.Q.; Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer\u2019s disease. Mol Psychiatry 2015,20(2),252-262","journal-title":"Mol Psychiatry"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neuropharm.2017.03.030","volume":"119","author":"Zhu H.","year":"2017","unstructured":"Zhu H.; Xue X.; Wang E.; Wallack M.; Na H.; Hooker J.M.; Kowall N.; Tao Q.; Stein T.D.; Wolozin B.; Qiu W.Q.; Amylin receptor ligands reduce the pathological cascade of Alzheimer\u2019s disease. Neuropharmacology 2017,119,170-181","journal-title":"Neuropharmacology"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.trci.2016.11.005","volume":"3","author":"Soudy R.","year":"2016","unstructured":"Soudy R.; Patel A.; Fu W.; Kaur K.; MacTavish D.; Westaway D.; Davey R.; Zajac J.; Jhamandas J.; Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer\u2019s disease. Alzheimers Dement (N Y) 2016,3(1),44-56","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s12035-016-9684-x","volume":"54","author":"Kimura R.","year":"2017","unstructured":"Kimura R.; MacTavish D.; Yang J.; Westaway D.; Jhamandas J.H.; Pramlintide antagonizes beta amyloid (A\u03b2)- and human amylin-induced depression of hippocampal long-term potentiation. Mol Neurobiol 2017,54(1),748-754","journal-title":"Mol Neurobiol"},{"key":"ref=153","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-515476\/v1","author":"Patel A.","year":"2021","unstructured":"Patel A.; Shiritsu S.; Tokyo Y.; Daigaku R.; Fu W.; Soudy R.; Genetic depletion of amylin\/calcitonin receptors improves memory and learning in transgenic Alzheimer\u2019s disease mouse models. Mol Neurobiol 2021","journal-title":"Mol Neurobiol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.2337\/diabetes.52.9.2315","volume":"52","author":"Bennett R.G.","year":"2003","unstructured":"Bennett R.G.; Hamel F.G.; Duckworth W.C.; An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 2003,52(9),2315-2320","journal-title":"Diabetes"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"18820","DOI":"10.1074\/jbc.M111.331181","volume":"287","author":"Fu W.","year":"2012","unstructured":"Fu W.; Ruangkittisakul A.; MacTavish D.; Shi J.Y.; Ballanyi K.; Jhamandas J.H.; Amyloid \u03b2 (A\u03b2) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 2012,287(22),18820-18830","journal-title":"J Biol Chem"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/cbic.201100192","volume":"12","author":"Andreetto E.","year":"2011","unstructured":"Andreetto E.; Yan L.; -.M.; Caporale, A.; Kapurniotu, A. Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of A\u03b240 amyloid formation and cytotoxicity. ChemBioChem 2011,12(9),1313-1322","journal-title":"ChemBioChem"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3233\/JAD-170948","volume":"62","author":"Tao Q.","year":"2018","unstructured":"Tao Q.; Zhu H.; Chen X.; Stern R.A.; Kowall N.; Au R.; Blusztajn J.K.; Qiu W.Q.; Pramlintide: The effects of a single drug injection on blood phosphatidylcholine profile for Alzheimer\u2019s disease. J Alzheimers Dis 2018,62(2),597-609","journal-title":"J Alzheimers Dis"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1100\/tsw.2001.23","volume":"1","author":"Edvinsson L.","year":"2001","unstructured":"Edvinsson L.; Goadsby P.J.; Uddman R.; Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. ScientificWorldJournal 2001,1,168-180","journal-title":"ScientificWorldJournal"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ana.25570","volume":"86","author":"Martinez-Valbuena I.","year":"2019","unstructured":"Martinez-Valbuena I.; Valenti-Azcarate R.; Amat-Villegas I.; Riverol M.; Marcilla I.; de Andrea C.E.; S\u00e1nchez-Arias J.A.; Del Mar Carmona-Abellan M.; Marti G.; Erro M.E.; Mart\u00ednez-Vila E.; Tu\u00f1on M.T.; Luquin M.R.; Amylin as a potential link between type 2 diabetes and alzheimer disease. Ann Neurol 2019,86(4),539-551","journal-title":"Ann Neurol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"6440","DOI":"10.2174\/1381612811319360005","volume":"19","author":"Cavallucci V.","year":"2013","unstructured":"Cavallucci V.; Ferraina C.; D\u2019Amelio M.; Key role of mitochondria in Alzheimer\u2019s disease synaptic dysfunction. Curr Pharm Des 2013,19(36),6440-6450","journal-title":"Curr Pharm Des"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3233\/JAD-170283","volume":"59","author":"Yu Q.","year":"2017","unstructured":"Yu Q.; Du F.; Douglas J.T.; Yu H.; Yan S.S.; Yan S.F.; \nMitochondrial dysfunction triggers synaptic deficits \nvia\nactivation of p38 MAP kinase signaling in differentiated Alzheimer\u2019s disease trans-mitochondrial cybrid cells.\n J Alzheimers Dis 2017,59(1),223-239","journal-title":"J Alzheimers Dis"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"18670","DOI":"10.1073\/pnas.1006586107","volume":"107","author":"Du H.","year":"2010","unstructured":"Du H.; Guo L.; Yan S.; Sosunov A.A.; McKhann G.M.; Yan S.S.; Early deficits in synaptic mitochondria in an Alzheimer\u2019s disease mouse model. Proc Natl Acad Sci USA 2010,107(43),18670-18675","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1242\/jcs.01130","volume":"117","author":"Miller K.E.","year":"2004","unstructured":"Miller K.E.; Sheetz M.P.; Axonal mitochondrial transport and potential are correlated. J Cell Sci 2004,117(Pt 13),2791-2804","journal-title":"J Cell Sci"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.expneurol.2009.01.011","volume":"218","author":"Swerdlow R.H.","year":"2009","unstructured":"Swerdlow R.H.; Khan S.M.; The Alzheimer\u2019s disease mitochondrial cascade hypothesis: an update. Exp Neurol 2009,218(2),308-315","journal-title":"Exp Neurol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.molmed.2017.06.003","volume":"23","author":"Fu W.","year":"2017","unstructured":"Fu W.; Patel A.; Kimura R.; Soudy R.; Jhamandas J.H.; Amylin receptor: A potential therapeutic target for Alzheimer\u2019s disease. Trends Mol Med 2017,23(8),709-720","journal-title":"Trends Mol Med"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.bbadis.2013.10.015","volume":"1842","author":"Wang X.","year":"2014","unstructured":"Wang X.; Wang W.; Li L.; Perry G.; Lee H.; -.G.; Zhu, X. Oxidative stress and mitochondrial dysfunction in Alzheimer\u2019s disease. Biochim Biophys Acta 2014,1842(8),1240-1247","journal-title":"Biochim Biophys Acta"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3233\/JAD-160800","volume":"56","author":"Mohamed L.A.","year":"2017","unstructured":"Mohamed L.A.; Zhu H.; Mousa Y.M.; Wang E.; Qiu W.Q.; Kaddoumi A.; Amylin enhances amyloid-\u03b2 peptide brain to blood efflux across the blood-brain barrier. J Alzheimers Dis 2017,56(3),1087-1099","journal-title":"J Alzheimers Dis"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"e88063","DOI":"10.1371\/journal.pone.0088063","volume":"9","author":"Qiu W.Q.","year":"2014","unstructured":"Qiu W.Q.; Wallack M.; Dean M.; Liebson E.; Mwamburi M.; Zhu H.; Association between Amylin and Amyloid-\u03b2 Peptides in Plasma in the Context of Apolipoprotein E4 Allele. PLoS One 2014,9(2),e88063","journal-title":"PLoS One"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666211201093147","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/198446\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666211201093147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T16:39:51Z","timestamp":1666888791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/198446\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":168,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x19666211201093147","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}